Bg Medicine company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bg-medicine.com

Founded Year

2000

Stage

IPO | IPO

Total Raised

$65.55M

Date of IPO

2/21/2011

Revenue

$0000 

About Bg Medicine

Bg Medicine is developing transformative in vitro and in vivo diagnostic products. BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare.Bg Medicine is developing multiple product candidates for cardiac and other diseases and have recently begun limited sales and marketing activities in Europe for the company's lead product, BGM Galectin-3. The company believe that its tests will provide clinicians with improved information to better detect and characterize disease states and that this improved information may enable physicians to achieve better patient outcomes and contain healthcare costs through:Earlier diagnosis,Segmentation based on underlying disease processes,More accurate prognosis, andPersonalized treatment selection or monitoring of disease based on disease activity.Bg Medicine's focus is on blood-based tests due to the ease and low cost of access to evaluable samples for testing and the opportunity for repeat sampling to monitor changes in a patient's medical condition.

Bg Medicine Headquarter Location

610 Lincoln Street North

Waltham, Massachusetts, 02451,

United States

781-890-1199

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Bg Medicine Patents

Bg Medicine has filed 8 patents.

The 3 most popular patent topics include:

  • Cardiac arrhythmia
  • Cardiology
  • Cardiovascular physiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/15/2010

3/1/2016

Cardiology, Heart diseases, Nutrition, Ischemic heart diseases, Lipid disorders

Grant

Application Date

11/15/2010

Grant Date

3/1/2016

Title

Related Topics

Cardiology, Heart diseases, Nutrition, Ischemic heart diseases, Lipid disorders

Status

Grant

Latest Bg Medicine News

Metabolomics Global Market Report 2022

Feb 18, 2022

" - https://www.reportlinker.com/p06229165/?utm_source=GNW , Dani Instruments S.P.A, Perkinelmer Inc., Evans Analytical Group LLC, LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G and Merck kgaA. The global metabolomics market is expected to grow from $2.35 billion in 2021 to $2.69 billion in 2022 at a compound annual growth rate (CAGR) of 14.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.79 billion in 2026 at a CAGR of 15.5%. The metabolomics market consists of sales of metabolomics analytical tools, equipment and related services.Metabolomics is the field of bio-analytics for quantification and identification of metabolic small molecules such as cell, tissue, organ and biological fluid. Metabolomics includes analytical instruments such as liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry and nuclear magnetic resonance spectroscopy. The main product and services of metabolomics are metabolomics instruments, metabolomics bioinformatics tools and services.Metabolomics instruments are devices used to extensively examine low-molecular-weight compounds in biological samples. The various metabolomics instruments include separation techniques, detection techniques and metabolomics bioinformatics tools and services involve bioinformatics tools and database, and bioinformatics services. The different indications are cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others which are applied in biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. Increasing prevalence rate of cancer drives the metabolomics market growth.Metabolomics screens the potential biomarkers (specific cells, molecules, or genes, gene products, enzymes, or hormones) to measure the cancer drug responsiveness aiding early diagnosis. For instance, according to a report by American Cancer Society in 2019, approximately 1,762,450 new cancer cases were diagnosed in the United States of which the most common cancers are lung cancer, breast cancer, prostate cancer and others.In 2020, according to American Cancer Society, lung cancer is the leading cancer killer in both men and women in the USA, there were 228,820 new cancer cases and 135,720 deaths. Metabolomics approaches such as nuclear magnetic resonance (NMR) technique and mass spectrometry (MS) techniques have been used to study cancer. Companies like Metabolon Inc., Bruker Corp, and others have adopted metabolomics as a tool for early detection and cure for cancer. The increasing complexity in interpreting data act as a restraint hindering the metabolomics market growth.Metabolomics tools generate huge quantum of data through metabolomics techniques and the generated data keeps changing not static, hence increasing the difficultly in interpretation of data. For instance, data generated by nuclear magnetic resonance (NMR) Spectroscopy, an analytical technique used for metabolic profiling (a method to measure and interpret various low molecular weight and other intermediates), is difficult to process and interpret. High-level statistical techniques are required for classification and analysis of this data to uncover the biological knowledge which is time-consuming and expensive, restraining the metabolomics market growth. Machine learning is increasing its popularity in the field of metabolomics due to improve efficiency in interpretation of data generated from metabolomics techniques.Machine learning enabled technologies help in automation of risky and complex processes, avoid repetitive and time taking processes, provide quick and error-free services. Companies in the industry are preferring machine learning techniques for metabolism analysis to solve problems, automate processes and execute tasks.Some of the machine learning algorithms aid in metabolism data analysis and metabolic pathway modelling. Some of the companies such as Bio-Rad Laboratories, Metabolon Inc and others have started using machine learning algorithms for better understanding and prediction in metabolomics study. For instance, MeltDB 2.0, a machine learning software used as a tool for the analysis and integration of metabolomics experiment data that aids research, store experimental data sets. Such machine learning software offer comprehensive analysis and visualization features for the proper representation of the large complex data. In January 2018, Biocrates Life Sciences AG, an Austria-based biotechnology company, acquired Metanomics Health GmbH, for an undisclosed amount.This acquisition would strengthen and improve Biocrates Life market share in early disease detection by leveraging the capabilities of Metanomics. Metanomics Health GmbH is a biotechnology company offering metabolomics in life sciences, providing analytical services of metabolite profiling, involved in marketing and developing tools to carry out research and development in healthcare sector. The company was founded in 2002 and is headquartered in Berlin, Germany. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Bg Medicine Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bg Medicine Rank

  • When was Bg Medicine founded?

    Bg Medicine was founded in 2000.

  • Where is Bg Medicine's headquarters?

    Bg Medicine's headquarters is located at 610 Lincoln Street North, Waltham.

  • What is Bg Medicine's latest funding round?

    Bg Medicine's latest funding round is IPO.

  • How much did Bg Medicine raise?

    Bg Medicine raised a total of $65.55M.

  • Who are Bg Medicine's competitors?

    Competitors of Bg Medicine include LineaGen Research, Intuity Medical, STARR Life Sciences, Mercator MedSystems, Novasom, Cardiac Science Corporation, Integrated Diagnostics, Minomic International, Daktari Diagnostics, Magellan Biosciences and 28 more.

You May Also Like

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

C
Cellatope Corporation

Cellatope is a cell analysis company that is developing research and diagnostic products and services in the field of autoimmune and inflammatory disease, with an initial focus on lupus and transplant medicine.

T
TeleMedTest

TeleMedTest developed acoustic and information technology to deliver highly accurate diagnostic test data with a significant reduction in cost and patient inconvenience compared to prevailing alternatives. The initial product, SonoUroFlow, measures the urinary flow rate of adults and children with dysfunctional voiding.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

Mediracer Logo
Mediracer

Mediracer Specialises In Medical Technology. The company's Core Business Is The Development, Manufacture And Global Sale Of Point Of Care (poc) Diagnostic Testing Equipment For Diseases Of The Peripheral Nervous System.

N
NeoDiagnostix

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.